Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say

Group 1 - Ultragenyx reported revenue of $139.29 million for the quarter ended March 2025, reflecting a 28% increase year-over-year [1] - The earnings per share (EPS) for the quarter was -$1.57, an improvement from -$2.03 in the same quarter last year [1] - The reported revenue was a slight miss of 1.90% compared to the Zacks Consensus Estimate of $141.99 million [1] Group 2 - Key metrics indicate that Ultragenyx shares have returned +20.9% over the past month, outperforming the Zacks S&P 500 composite's +11.5% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Group 3 - Product sales for Mepsevii reached $8.39 million, exceeding the average estimate of $7.63 million from seven analysts [4] - Dojolvi product sales were reported at $17.01 million, below the estimated $21.47 million, but showed a 4% increase compared to the previous year [4] - Evkeeza product sales were $11.03 million, surpassing the average estimate of $10.58 million, with a significant year-over-year increase of 236.8% [4] - Total product sales amounted to $91.51 million, exceeding the average estimate of $75.76 million based on four analysts, representing a year-over-year change of 46.4% [4]